Drug Profile
SR 13668
Alternative Names: SR13668Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator SRI International
- Class Antineoplastics
- Mechanism of Action Proto oncogene protein c-akt inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-0 development in Cancer(Prevention) in USA (PO)
- 13 Oct 2009 Phase-0 for Cancer in USA (PO)